Company intelligence / Profile preview

广州瑞安博医药科技

Guangzhou, Guangdong, China

Ownership: Private
Development stage: Other

Overview

Reborn Therapeutics is a clinical-stage biopharmaceutical company headquartered in Guangzhou, China, specializing in the development of next-generation targeted protein degradation (TPD) therapies. The company leverages its proprietary Re-Glue platform to discover and develop molecular glue degraders and PROTACs for challenging targets in oncology and immunology. Its lead candidate, RB-001, is a potent molecular glue degrader targeting GSPT1, currently undergoing clinical evaluation for the treatment of advanced solid tumors. Reborn aims to address unmet medical needs by converting undruggable proteins into therapeutic opportunities through innovative small molecule design and advanced screening technologies.

Therapeutic areas: Oncology
Modalities: Molecular glue therapyProteolysis-targeting chimera therapySmall molecule
Industry: Biotech

Beyond the preview

Go deeper on 广州瑞安博医药科技.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 广州瑞安博医药科技.

Explore the full profile